| Patient | Flannery O'Connor |
|---|---|
| Date of birth | 2001-03-25 |
| Identifiers | MRN HR-ML046-SYN; SSN (made up) 000-46-1853 |
| Document date | 2026-10-26 |
| Author | Augusta Pemberton-Diallo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month review of lupus nephritis; pregnancy planning. [S]
Ms. O'Connor is six months into treatment. She reached prednisone 5 mg a day a week ago. Her joints and skin remain quiet; she has had no fevers, infections, or hip pain since the summer. Monthly blood counts have been normal. She had her influenza vaccine at the preventive visit three weeks ago. She has finished a draft of her novel. She would like to have children in a few years and asked what that would mean for her treatment. [S]
| Element | Detail |
|---|---|
| Interval change | Prednisone 5 mg a day; no flares or infections |
| Medicines | Mycophenolate 2 g a day; belimumab weekly; hydroxychloroquine 300 mg; losartan 25 mg; vitamin D3 |
| Question | Pregnancy in a few years |
| Work | Draft of her novel finished |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight falling |
| Musculoskeletal | Negative | No joint pain; no hip, groin, or knee pain |
| Integumentary | Negative | No rash; hair regrowing |
| Genitourinary | Negative | No urinary symptoms |
| Psychiatric | Negative | Mood good; PHQ-9 3 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 2026-04-13 | active | S |
| Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long term | One tablet once daily | Oral route | 2026-04-22 | active | S |
| Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressure | One tablet once daily | Oral route | 2026-04-22 | active | S |
| Methylprednisolone 500 mg intravenous infusion once daily for three days | One infusion daily for three days | Intravenous route | 2026-04-29 to 2026-05-01 | completed | S |
| Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six months | Once daily, tapering | Oral route | 2026-04-29 | active | S |
| Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice daily | Two tablets twice daily | Oral route | 2026-04-29 | active | S |
| Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weekly | Once weekly by self-injection | Subcutaneous route | 2026-04-29 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-04-29 | active | S |
| Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for seven days | One capsule twice daily for seven days | Oral route | 2026-06-15 to 2026-06-21 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-26 | Body height | 168 | cm | S |
| 2026-10-26 | Body weight | 62 | kg | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 2026-10-26 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-10-26 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-26 | Heart rate | 72 | /min | S |
| 2026-10-26 | Respiratory rate | 14 | /min | S |
| 2026-10-26 | Body temperature | 36.6 | Cel | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-26 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-10-26 | Leukocytes [#/volume] in Blood by Automated count | 5.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-26 | Lymphocytes [#/volume] in Blood by Automated count | 1.2 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 2026-10-26 | Platelets [#/volume] in Blood by Automated count | 236 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-26 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | <=33 U/L | Normal | S |
| 2026-10-26 | Protein/Creatinine [Mass Ratio] in Urine | 0.35 | g/g | <=0.2 g/g | High | S |
| 2026-10-26 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 2 | /[HPF] | <=2 /[HPF] | Normal | S |
| 2026-10-26 | DNA double strand Ab [Units/volume] in Serum | 38 | [IU]/mL | <=29 [IU]/mL | High | S |
| 2026-10-26 | Complement C3 [Mass/volume] in Serum or Plasma | 96 | mg/dL | 90-180 mg/dL | Normal | S |
| 2026-10-26 | Complement C4 [Mass/volume] in Serum or Plasma | 18 | mg/dL | 10-40 mg/dL | Normal | S |
| 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-10-26 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 0 | {score} | S |
Vital signs recorded on 2026-10-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Skin | No rash; no mouth ulcers |
| Musculoskeletal | No synovitis; full, painless hip movement |
| Cardiovascular | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Pain and swelling of the small joints of both hands, the wrists, and the knees for three months, with an hour of morning stiffness, evening fevers to 38 °C, fatigue, and a red rash over the cheeks and nose after sun; told elsewhere it might be rheumatoid arthritis; cause to be established | resolved | confirmed | M25.50 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis of systemic lupus erythematosus at the second visit; joint pain in 1950 with suspected rheumatoid arthritis is documented (D). |
| Protein and blood in the urine: protein-to-creatinine ratio 1.6 g/g and 18 red cells per high-power field, with normal creatinine; cause to be established | resolved | confirmed | R80.9 | S — Synthetic presenting finding at the index visit, superseded by the kidney biopsy diagnosis at the third visit. |
| Systemic lupus erythematosus, classified by the EULAR/ACR criteria (ANA 1:640 homogeneous; score 32 before the biopsy): inflammatory arthritis, acute cutaneous lupus (malar rash), fever, leukopenia with lymphopenia, mild thrombocytopenia, low C3 and C4, anti-dsDNA and anti-Sm positive; antiphospholipid antibodies and lupus anticoagulant negative | active | confirmed | M32.19 | S — Synthetic modern diagnosis and results; her systemic lupus erythematosus, diagnosed in Atlanta in late 1950 or early 1951, is documented (D), but no finding from her lifetime is used. |
| Lupus nephritis, ISN/RPS class III (A), focal proliferative, on kidney biopsy: endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence; no thrombotic microangiopathy; urine protein-to-creatinine ratio 1.8 g/g; normal kidney function | active | confirmed | M32.14 | S — Synthetic biopsy result and class; kidney involvement is documented at the end of her life, but no kidney finding from her lifetime is used. |
| Long-term glucocorticoid treatment for lupus nephritis, tapering to 5 mg a day or less | active | confirmed | Z79.52 | S — Synthetic treatment status; the documented steroid harm in her life is the reason the episode keeps glucocorticoids low. |
| Long-term mycophenolate mofetil, with belimumab, for lupus nephritis; bone and infection protection in place | active | confirmed | Z79.624 | S — Synthetic treatment status. |
| Levonorgestrel intrauterine system for highly effective contraception during mycophenolate treatment | active | confirmed | Z97.5 | S — Synthetic contraception, chosen by the patient. |
| Acute cystitis on mycophenolate, belimumab, and prednisone 15 mg: two days of burning, frequency, and urgency without fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; resolved with seven days of nitrofurantoin | resolved | confirmed | N30.00 | S — Synthetic common infection in an immunosuppressed young woman; coded without hematuria because the persistent hematuria is from her nephritis. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Urine protein-to-creatinine ratio and urine sediment | Every 3 months during active treatment | Completed today | 0.35 g/g; 2 red cells per high-power field: complete renal response |
| Laboratory | Creatinine, eGFR, albumin, and potassium | Every 3 months during active treatment | Completed today | Creatinine 0.8, eGFR 101, albumin 4.1, potassium 4.3 |
| Laboratory | Anti-dsDNA, C3, and C4 | Every 3 months during active treatment | Completed today | Anti-dsDNA 38; C3 96; C4 18 |
| Laboratory | Blood count and liver tests on mycophenolate | Monthly in the first year | Completed today | White cells 5.6, lymphocytes 1.2, hemoglobin 12.8, platelets 236; ALT 20 |
| Examination | Blood pressure | Every visit | Completed today | 118/76 mmHg |
| Medication safety | Glucocorticoid dose | Every visit | Completed today | Prednisone 5 mg a day at six months, as planned |
| Examination | Avascular necrosis symptoms | Every visit | Completed today | No hip, groin, or knee pain |
| Imaging | Bone density (DXA) | Every 1 to 3 years on glucocorticoids | Up to date | Normal six months ago |
| Medication safety | Hydroxychloroquine eye screening | Yearly from five years of use | Up to date | Baseline normal four months ago |
| Medication safety | Vaccinations | Yearly influenza; others as due | Up to date | Influenza three weeks ago; PCV20 and two zoster doses done; COVID-19 booked |
| Medication safety | Contraception and pregnancy planning | Every visit | Completed today | Intrauterine system in place; pregnancy plan discussed |
| Laboratory | Anti-Ro and anti-La antibodies | Before pregnancy | Due | When she plans a pregnancy |
| Laboratory | Lipids | Yearly on glucocorticoids | Due | At one year |
| Survey | Mood on belimumab (PHQ-9) | Periodically | Completed today | PHQ-9 3 |
| Survey | Joint pain score | Every visit | Completed today | 0 of 10 |
| Self-management | Sun protection and writing schedule | Every visit | Completed today | Sunscreen daily; draft of her novel finished |
Goal progress:
Guideline basis: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023); 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024); 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res 2020;72(4):461-488 (2020); CELLCEPT (mycophenolate mofetil): prescribing information (blood count monitoring, embryofetal toxicity, contraception) (2026); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease and hypertension monographs (2026)
Follow-up: Rheumatology every three months with kidney panel, urine protein, and serology. Blood counts monthly to one year. Primary care review in three months. [S]